» Articles » PMID: 15684713

Internalization of Exogenous Human Immunodeficiency Virus-1 Protein, Tat, by KG-1 Oligodendroglioma Cells Followed by Stimulation of DNA Replication Initiated at the JC Virus Origin

Overview
Journal DNA Cell Biol
Publisher Mary Ann Liebert
Date 2005 Feb 3
PMID 15684713
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

JC virus (JCV) is the etiological agent of an opportunistic brain infection, progressive multifocal leukoencephalopathy (PML), in AIDS. PML is fatal in approximately 4% of HIV-infected individuals, and although the overall incidence has fallen due to highly aggressive antiretroviral therapy (HAART), this percent has remained steady. It has been shown that the Tat protein of human immunodeficiency virus-1 (HIV-1) interacts in cells with cellular protein Puralpha. This interaction can stimulate transcription of both HIV-1 and JCV genes. HIV-1, however, infects primarily microglia and astrocytes in the brain, whereas JCV infects primarily oligodendrocytes. Although HIV-1 has been shown capable of infecting oligodendrocytes in vitro (Albright et al., 1996), no instance of viral coinfection of such cells with JCV has been reported. Tat is known to be secreted from cells in which it is made. Here we ask whether such exogenous Tat can influence JCV replication in oligodendrocytes. We find that glial cells infected with either HIV-1 or JCV are in proximity at the outer edge of PML lesions. Exogenous Tat is avidly incorporated into cultured KG-1 oligodendroglioma cells over a 72-h period and is colocalized with endogenous Puralpha both nuclear and juxtanuclear. At concentrations in the medium well below the pM range, Tat stimulates several-fold the replication in vivo of DNA initiated at the JCV origin. These results define a pathway by which a protein made by HIV-1 can directly affect the course of infection by another disease-causing virus.

Citing Articles

Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.

Corey S, Smith B, Cortese I Curr HIV/AIDS Rep. 2022; 19(6):580-591.

PMID: 36181625 PMC: 9759507. DOI: 10.1007/s11904-022-00626-w.


Unconventional Protein Secretion in Brain Tumors Biology: Enlightening the Mechanisms for Tumor Survival and Progression.

Iglesia R, Prado M, Alves R, Escobar M, Fernandes C, Fortes A Front Cell Dev Biol. 2022; 10:907423.

PMID: 35784465 PMC: 9242006. DOI: 10.3389/fcell.2022.907423.


Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV.

Pinnetti C, Cimini E, Vergori A, Mazzotta V, Grassi G, Mondi A Viruses. 2022; 14(5).

PMID: 35632711 PMC: 9146231. DOI: 10.3390/v14050970.


Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Cortese I, Reich D, Nath A Nat Rev Neurol. 2020; 17(1):37-51.

PMID: 33219338 PMC: 7678594. DOI: 10.1038/s41582-020-00427-y.


Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML).

Khalili A, Craigie M, Donadoni M, Sariyer I J Neuroimmune Pharmacol. 2019; 14(4):649-660.

PMID: 31452013 PMC: 6898772. DOI: 10.1007/s11481-019-09877-8.